Showing results (91-100 of 224) with videos related to

Sort By:
Pageof 23
Frontiers in Immunology|March 3, 2025
Factor B as a therapeutic target for the treatment of complement-mediated diseasesDavid Kavanagh, Jonathan Barratt, Anna Schubart, et al.
American Journal of Nephrology|October 27, 2015
Intervention Associated Acute Kidney Injury and Long-Term Cardiovascular OutcomesAthanasios Saratzis, Seamus Harrison, Jonathan Barratt, et al.
Kidney International Reports|August 13, 2021
A Pilot Study to Predict Risk of IgA Nephropathy Progression Based on miR-204 ExpressionIzabella Pawluczyk, Matthew Nicholson, Sean Barbour, et al.
Kidney International Reports|December 22, 2025
Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in ManagementJonathan Barratt, Laura H Mariani, Jai Radhakrishnan, et al.
Advances in Therapy|February 16, 2024
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 TrialsTakayuki Hamano, Yusuke Yamaguchi, Kashia Goto, et al.
Kidney360|December 26, 2024
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial ResultsHong Zhang, Richard Lafayette, Bei Wang, et al.
Advances in Therapy|February 16, 2024
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in JapanTakayuki Hamano, Yusuke Yamaguchi, Kashia Goto, et al.
Kidney International Reports|November 9, 2020
Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA NephropathyRichard A Lafayette, Brad H Rovin, Heather N Reich, et al.
Advances in Therapy|February 7, 2023
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 StudiesJonathan Barratt, Frank Dellanna, Jose Portoles, et al.
Kidney International Reports|May 16, 2022
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy VolunteersMohit Mathur, Jonathan Barratt, Yusuke Suzuki, et al.
Pageof 23